U.S. Specialty Stores Stock News

OFG Bancorp recently reported its first-quarter 2026 results, with net interest income of US$153.81 million and net income of US$53.94 million, both higher than a year earlier, and basic earnings per share from continuing operations of US$1.26. This improvement in profitability, driven by higher net interest income, offers fresh context for assessing OFG Bancorp’s earnings resilience and balance sheet management. Next, we’ll examine how this stronger net interest income performance may...

Flagstar Bank, N.A. has opened its third Private Client Office at 300 California Street in San Francisco, a two-floor, 6,400-square-foot space designed for 23 bankers and multiple conference rooms to serve affluent and high-net-worth clients, business owners, entrepreneurs, family offices, and professional service firms. The bank’s decision to mirror its New York City and Palm Beach concierge-style design and concentrate private banking expertise in San Francisco underlines its commitment to...

Earlier this year, CBRE Group and Meta launched LevelUp, a multiyear program to recruit and train thousands of fiber technicians across multiple U.S. training centers, supporting the build-out of next-generation data center infrastructure. This partnership, combined with analysts’ expectations for higher quarterly earnings and revenue, highlights CBRE’s deepening role in data center-related services and operational execution. Next, we’ll assess how CBRE’s Meta partnership and data center...

Why Chord Energy is on investors’ radar today Chord Energy (CHRD) has been drawing attention after recent share price moves, with the stock up about 2.8% over the past day but showing mixed returns across the week, month and past 3 months. See our latest analysis for Chord Energy. Zooming out from the 2.8% one day share price gain to around $127, Chord Energy’s 90 day share price return of 38.23% and 1 year total shareholder return of 44.06% indicate that momentum has been building rather...

In April 2026, NGL Energy Partners LP announced that its Board of Directors had approved an open-ended unit repurchase program of up to US$100 million of its outstanding limited partnership units. This sizable buyback authorization stands out as a capital allocation move that can tighten the unit count and reflect management’s confidence in the partnership’s outlook. With that backdrop, we’ll now examine how this US$100 million repurchase authorization shapes NGL Energy Partners’ investment...

Why the AACR data on rinzimetostat is on investors’ radar ORIC Pharmaceuticals (ORIC) shares are in focus after the company highlighted new preclinical data for rinzimetostat at the 2026 AACR Annual Meeting, centered on prostate cancer models that include treatment resistant disease. See our latest analysis for ORIC Pharmaceuticals. ORIC’s latest AACR posters on rinzimetostat arrive after a strong year to date, with a 33.29% year to date share price return and a 123.61% 1 year total...

Camden Property Trust (CPT) has entered into a binding term sheet to settle a class action lawsuit, agreeing to contribute US$53 million to a settlement fund and to adopt specific business practice commitments, subject to court approval. See our latest analysis for Camden Property Trust. After this settlement announcement, Camden Property Trust’s recent share price momentum has been improving, with a 7.60% 1 month share price return. However, the year to date share price return is still...

Septerna, Inc. recently began dosing healthy volunteers in a randomized, placebo-controlled Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, using single-ascending and multiple-ascending dose designs to assess safety, tolerability, pharmacokinetics and pharmacodynamics. This first-in-human study, which could enroll up to 150 participants and tracks biomarkers such as endogenous PTH and serum calcium, marks a key progression of Septerna’s GPCR-targeted pipeline into...

California Water Service Group (CWT) has attracted fresh attention after recent share price moves, with the stock showing gains over the past week, month, and past 3 months relative to its last close of $46.85. See our latest analysis for California Water Service Group. That recent 4.2% 1 day share price return and 6.7% 30 day share price return sit against a 1 year total shareholder return decline of 5.2%. This suggests short term momentum is improving while longer term returns remain under...

Over the last 7 days, the United States market has risen by 3.6%, and over the past year, it has seen a remarkable increase of 39%, with earnings forecasted to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer opportunities for investors looking to capitalize on discrepancies between current prices and estimated worth.

Context for Vertex Pharmaceuticals after recent share performance Vertex Pharmaceuticals (VRTX) has recently seen its share price under pressure, with a 3.3% decline over the past month and an 8.0% negative total return over the past year. This performance has prompted closer attention from investors. See our latest analysis for Vertex Pharmaceuticals. With the share price at US$439.18 and a 1 year total shareholder return of 8.0% in the red, but a 5 year total shareholder return of 102.4%,...

Marriott International’s Luxury Collection is partnering with designer Margherita Maccapani Missoni on an immersive Milan Design Week pop-up and capsule fashion collection at Casa Brera, while also advancing its Autograph Collection footprint with the NUMAJ hotel in Saudi Arabia’s AlUla and opening the Noormahal Palace Hotel in Karnal, India. Together, these moves highlight Marriott’s push to deepen its luxury positioning by blending high-end hospitality with fashion-led experiences and...

The United States market has shown robust performance, climbing 3.6% in the last week and 39% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and strategic direction.

Over the last 7 days, the United States market has risen 3.6%, and over the past year, it has climbed 39%, with earnings expected to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for investors seeking growth at lower price points. By focusing on those with strong balance sheets and solid fundamentals, these stocks can present an underappreciated chance for stability and potential upside in today's market conditions.

Recent performance snapshot Zurn Elkay Water Solutions (ZWS) has attracted investor attention following a period in which the stock posted a modest one-day move, weaker performance over the past week, and positive returns over the past month and past three months. See our latest analysis for Zurn Elkay Water Solutions. At a share price of $47.78, Zurn Elkay Water Solutions has recently paired a weaker 7 day share price return with a stronger 1 month share price return, while its 1 year total...

Under Armour (UAA) is back in the spotlight after Unrivaled Sports announced new partnerships with the brand and DICK'S Sporting Goods, focused on youth sports programming nationwide and exclusive apparel roles at marquee events. See our latest analysis for Under Armour. Investors have seen momentum build recently, with a 7 day share price return of 7.65% and a 30 day share price return of 12.99%. At the same time, the 1 year total shareholder return of 15.16% contrasts with a 5 year total...

Morgan Stanley recently elevated Affirm Holdings to its Top Pick list, arguing that concerns around private credit are too pessimistic and pointing to upcoming company updates on gross merchandise volume, margins, and long-term earnings targets at its May Investor Forum as important reference points. An interesting angle is Morgan Stanley’s expectation that Affirm will outline a fiscal 2028 GAAP EPS range that the bank views as conservative, potentially reframing how investors think about...

The United States market has experienced a notable upswing, climbing 3.6% over the last week and an impressive 39% over the past year, with earnings projected to grow by 16% annually. In such a dynamic environment, identifying stocks that are not only poised for growth but also remain under the radar can offer unique opportunities for investors seeking to capitalize on market momentum while discovering potential value.

What recent performance says about East West Bancorp East West Bancorp (EWBC) has drawn attention after a strong month, with the stock showing a 15% return and a gain of about 6% over the past 3 months. This recent performance has prompted some investors to reassess its valuation. See our latest analysis for East West Bancorp. Putting that move in context, the 15.0% 1 month share price return sits alongside a 3.5% year to date share price return and a 60.2% 1 year total shareholder return...

Royal Caribbean Cruises (RCL) has been back on investors’ radar after its stock rallied when Iran temporarily reopened the Strait of Hormuz, easing supply concerns, along with upbeat commentary on the company’s use of artificial intelligence. See our latest analysis for Royal Caribbean Cruises. Beyond the latest geopolitical and AI headlines, Royal Caribbean’s share price has had a mixed few months, with a 7.06% 1 month share price return and a 51.14% 1 year total shareholder return that...

In April 2026, Marsh & McLennan Companies reported first-quarter 2026 results showing sales of US$7,597 million, net income of US$1,146 million, and lower earnings per share year over year, alongside confirmation that it completed a US$1,074.65 million buyback covering 1.23% of shares since November 2025. While revenue increased compared with the prior year, the combination of declining net income and earnings per share with continued share repurchases highlights a shift in the balance...

GRAIL (GRAL) stock is drawing attention after back to back announcements that extend access to its Galleri multi cancer early detection blood test through Epic’s electronic health record platform and Junction’s digital health infrastructure. See our latest analysis for GRAIL. Investors appear to be weighing these new distribution partnerships against a tougher recent trading history, with the share price at US$51.20, a 7 day share price return of 6.6% and a 90 day share price return showing a...

Cedar Grove Capital Management’s latest Q1 2026 investor letter put RealReal (REAL) in focus, pointing to its role in the fast growing second hand luxury market and recent operational and profitability metrics. See our latest analysis for RealReal. RealReal’s share price has been volatile, with a 36.9% 1 month share price return and a 25.1% decline year to date, while 1 year total shareholder return is 124.5%. If this kind of rebound catches your eye, it could be worth broadening your...

Earlier this month, Ultragenyx Pharmaceutical reported that the US FDA accepted its resubmitted Biologics License Application for UX111, an investigational AAV9 gene therapy for Sanfilippo syndrome Type A, and set a PDUFA action date of 19 September. If UX111 is ultimately approved, it could become the first available treatment for this rare, fatal pediatric neurodegenerative disorder, marking a potentially important expansion of Ultragenyx’s rare-disease gene therapy portfolio. We’ll now...